{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:10:12Z","timestamp":1786975812237,"version":"build-2736575974"},"reference-count":24,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:sec id=\"ab-eoi260022-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Geographic atrophy (GA) enlargement rates are generally stable over time for any given eye, a property which may help improve GA clinical trial efficiency by preserving statistical power with smaller sample sizes. One strategy is to incorporate a run-in phase into randomized clinical trials (RCT) to collect natural history data before randomization, while another strategy is a single-arm trial, in which all participants receive the study drug and enlargement rates are compared between run-in and treatment phases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi260022-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate whether run-in phase RCTs or single-arm trial designs might improve trial efficiency using power analyses and trial simulations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi260022-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>\n                      This diagnostic\/prognostic study uses in silico clinical trial power analyses. Parameters were derived from participants in the GA Minocycline Trial with baseline GA area of 2.5 to 17.5 mm\n                      <jats:sup>2<\/jats:sup>\n                      . Data were analyzed from November 2025 to March 2026.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi260022-7\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>The primary outcome was the required sample size for a given power, using square root GA area as the trial outcome. Sample size requirements for 80% and 90% power were estimated using linear mixed-model analyses and validated empirically by trial simulations (10\u202f000 replications), assuming 25% treatment effect and \u03b1\u2009=\u2009.05. First, RCTs (1:1 randomization) with vs without a run-in phase were compared, keeping total follow-up constant. Second, RCTs were compared with a single-arm trial of equal duration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi260022-8\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The Geographic Atrophy Minocycline Trial comprised 133 visits, 28 eyes, and 28 participants. The sample size estimate was smaller for an RCT with vs without a run-in phase. Sample size was incrementally smaller with longer run-in duration. For 2-year trials with 90% power, the sample size was 156 for an RCT vs 82, 40, and 26 for RCTs with run-in phases of 3, 6, and 9 months, respectively. Sample size estimates were smaller for single-arm trials than RCTs. The sample size for a 2-year single-arm trial (9-month run-in phase and 15-month treatment) was 14 vs 26 for an RCT (same phase durations). For all comparisons, similar patterns were observed for trials with 1-year duration, 80% power, nonsubfoveal GA only, or untransformed enlargement rates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi260022-9\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>For GA clinical trials, this diagnostic\/prognostic study suggests incorporating run-in phases into RCTs or using single-arm designs can improve trial efficiency by exploiting the inherent stability of GA enlargement rates. These sample size estimates may apply to a wide range of GA trial designs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaophthalmol.2026.1380","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T15:32:25Z","timestamp":1778772745000},"page":"529","source":"Crossref","is-referenced-by-count":1,"title":["Improving Efficiency in Geographic Atrophy Clinical Trials Using Run-In Phases or Single-Arm Designs"],"prefix":"10.1001","volume":"144","author":[{"given":"Jintong","family":"Hou","sequence":"first","affiliation":[{"name":"Division of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon","family":"von der Emde","sequence":"additional","affiliation":[{"name":"Division of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, Maryland"},{"name":"Department of Ophthalmology, University of Bonn, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souvick","family":"Mukherjee","sequence":"additional","affiliation":[{"name":"Division of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Vance","sequence":"additional","affiliation":[{"name":"Division of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tharindu","family":"de Silva","sequence":"additional","affiliation":[{"name":"Division of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangbo Linus","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Duke University School of Medicine, Durham, North Carolina"},{"name":"Department of Ophthalmology, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiarn\u00e1n D. L.","family":"Keenan","sequence":"additional","affiliation":[{"name":"Division of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"eoi260022r1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2024.102484","article-title":"Therapeutic innovations for geographic atrophy: a promising horizon.","volume":"78","author":"de Oliveira Figueiredo","year":"2024","journal-title":"Curr Opin Pharmacol"},{"key":"eoi260022r2","doi-asserted-by":"publisher","first-page":"321","DOI":"10.2147\/OPTH.S367089","article-title":"Emerging treatment options for geographic atrophy (GA) secondary to age-related macular degeneration.","volume":"17","author":"Khan","year":"2023","journal-title":"Clin Ophthalmol"},{"issue":"6","key":"eoi260022r3","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.3390\/biomedicines11061548","article-title":"Methodological appraisal of phase 3 clinical trials in geographic atrophy.","volume":"11","author":"Biarn\u00e9s","year":"2023","journal-title":"Biomedicines"},{"issue":"10411","key":"eoi260022r4","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1016\/S0140-6736(23)01520-9","article-title":"Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials.","volume":"402","author":"Heier","year":"2023","journal-title":"Lancet"},{"issue":"10411","key":"eoi260022r5","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/S0140-6736(23)01583-0","article-title":"Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial.","volume":"402","author":"Khanani","year":"2023","journal-title":"Lancet"},{"issue":"2","key":"eoi260022r6","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1159\/000510507","article-title":"Growth rate of geographic atrophy secondary to age-related macular degeneration: a meta-analysis of natural history studies and implications for designing future trials.","volume":"64","author":"Wang","year":"2021","journal-title":"Ophthalmic Res"},{"issue":"9","key":"eoi260022r7","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.oret.2020.12.002","article-title":"Geographic atrophy growth is strongly related to lesion perimeter: unifying effects of lesion area, number, and circularity on growth.","volume":"5","author":"Shen","year":"2021","journal-title":"Ophthalmol Retina"},{"issue":"2","key":"eoi260022r8","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.ophtha.2006.09.016","article-title":"The long-term natural history of geographic atrophy from age-related macular degeneration: enlargement of atrophy and implications for interventional clinical trials.","volume":"114","author":"Sunness","year":"2007","journal-title":"Ophthalmology"},{"issue":"12","key":"eoi260022r9","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1016\/j.ophtha.2018.05.028","article-title":"Progression of geographic atrophy in age-related macular degeneration: AREDS2 report number 16.","volume":"125","author":"Keenan","year":"2018","journal-title":"Ophthalmology"},{"issue":"8","key":"eoi260022r10","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.ophtha.2020.02.009","article-title":"A deep learning model for segmentation of geographic atrophy to study its long-term natural history.","volume":"127","author":"Liefers","year":"2020","journal-title":"Ophthalmology"},{"issue":"1","key":"eoi260022r11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.oret.2022.08.022","article-title":"Treating geographic atrophy-are we ready? a call to image.","volume":"7","author":"Guymer","year":"2023","journal-title":"Ophthalmol Retina"},{"issue":"4","key":"eoi260022r12","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2021.100057","article-title":"Local complement inhibition for geographic atrophy in age-related macular degeneration: prospects, challenges, and unanswered questions.","volume":"1","author":"Keenan","year":"2021","journal-title":"Ophthalmol Sci"},{"key":"eoi260022r13","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ajo.2025.03.021","article-title":"Phase 2 study of the anti-high temperature requirement A1 (HtrA1) fab galegenimab (FHTR2163) in geographic atrophy secondary to age-related macular degeneration.","volume":"275","author":"Eichenbaum","year":"2025","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"eoi260022r14","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1001\/jamaophthalmol.2024.0118","article-title":"Phase 2 trial evaluating minocycline for geographic atrophy in age-related macular degeneration: a nonrandomized controlled trial.","volume":"142","author":"Keenan","year":"2024","journal-title":"JAMA Ophthalmol"},{"issue":"10","key":"eoi260022r15","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.oret.2018.03.001","article-title":"A randomized phase 2 study of an anti-amyloid \u00df monoclonal antibody in geographic atrophy secondary to age-related macular degeneration.","volume":"2","author":"Rosenfeld","year":"2018","journal-title":"Ophthalmol Retina"},{"issue":"11","key":"eoi260022r16","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1002\/sim.8086","article-title":"Using simulation studies to evaluate statistical methods.","volume":"38","author":"Morris","year":"2019","journal-title":"Stat Med"},{"issue":"3","key":"eoi260022r17","doi-asserted-by":"publisher","first-page":"937","DOI":"10.2307\/2533554","article-title":"Sample size calculations for studies with correlated observations.","volume":"53","author":"Liu","year":"1997","journal-title":"Biometrics"},{"issue":"4","key":"eoi260022r19","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1177\/009286150804200402","article-title":"Recommendations for the primary analysis of continuous endpoints in longitudinal clinical trials.","volume":"42","author":"Mallinckrodt","year":"2008","journal-title":"Drug Inf J"},{"issue":"2","key":"eoi260022r20","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ophtha.2019.07.011","article-title":"Complement C3 inhibitor pegcetacoplan for geographic atrophy secondary to age-related macular degeneration: a randomized phase 2 trial.","volume":"127","author":"Liao","year":"2020","journal-title":"Ophthalmology"},{"issue":"4","key":"eoi260022r21","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.ophtha.2020.08.027","article-title":"C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration: a randomized pivotal phase 2\/3 trial.","volume":"128","author":"Jaffe","year":"2021","journal-title":"Ophthalmology"},{"issue":"3","key":"eoi260022r22","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2023.100440","article-title":"Metformin for the minimization of geographic atrophy progression (METforMIN): a randomized trial.","volume":"4","author":"Shen","year":"2023","journal-title":"Ophthalmol Sci"},{"issue":"6","key":"eoi260022r23","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1001\/jamaophthalmol.2018.1544","article-title":"Efficacy and safety of lampalizumab for geographic atrophy due to age-related macular degeneration: chroma and spectri phase 3 randomized clinical trials.","volume":"136","author":"Holz","year":"2018","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"eoi260022r24","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ophtha.2017.08.038","article-title":"The progression of geographic atrophy secondary to age-related macular degeneration.","volume":"125","author":"Fleckenstein","year":"2018","journal-title":"Ophthalmology"},{"key":"eoi260022r18","unstructured":"Donohue? MC, Edland? SD, Hu? N. Package \u2018longpower\u2019: sample size calculations for longitudinal data. CRAN. Accessed January 12, 2026. https:\/\/cran.r-project.org\/web\/packages\/longpower\/longpower.pdf"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2848898\/jamaophthalmology_hou_2026_oi_260022_1781021764.27261.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T15:01:00Z","timestamp":1781794860000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2848898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2026.1380","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,1]]}}}